Sagimet Biosciences dropped 9% after Ascletis Pharma’s Phase 3 Denifanstat safety data focused on tolerability, not new ...

HONG KONG, Jan. 29, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced positive topline results from the Phase III open-label study (NCT06248008) evaluating denifanstat ...

Scientists have discovered an enzyme that drives fat production and shown that blocking it prevents weight gain and lowers ...

Denifanstat showed tolerability and a favourable safety profile and most TEAEs were mild or moderate.

AOD-9604 is a growth hormone–derived peptide studied for fat metabolism, lipolysis, and potential cartilage regeneration in ...

Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The ...

Familial Hypobetalipoproteinemia (FHBL), caused by variants in the apolipoprotein B (APOB) gene, is a rare autosomal ...

From traditional cooling drinks of coastal India to modern functional food research, kokum reveals how ancient dietary ...